drugset / Trial / NCT01338870
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.
Timeline
- Start
- 2011-06
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04991532 | Small molecule | 25 mg | — |
| Subject | PF-04991532 | Small molecule | 75 mg | — |
| Subject | PF-04991532 | Small molecule | 150 mg | — |
| Subject | PF-04991532 | Small molecule | 300 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |